Chong Kun Dang Signs Nesp Biosimilar Deal In Persian Gulf
Deal With Oman-Based Menagen Expands Access To Darbepoetin Alfa
Chong Kun Dang’s Nesbell (darbepoetin alfa) biosimilar is set to head to the Persian Gulf under a technology transfer and commercialization agreement with Oman-based Menagen Pharmaceutical Industries.
You may also be interested in...
Asia Deal Watch: GC Pharma Looks To Build On Enzyme Replacement Therapy Success
South Korean firm teams with Speragen to develop enzyme-replacement therapy for the genetic disorder and with Mirum for maralixibat. Plus deals involving Takeda/PeptiDream, Hanmi/LegoChem, Sun/Cassiopea, LegoChem/Cellectar, ChubLab/CJ CheilJedang Corp., Alebund/Chugai, Kintor/Fosun, Astellas/ExCellThera and I-Mab/neoX/Immorna.
Alvogen’s Lotus Picks Up Darbepoetin Alfa Rights In Asia
Lotus Pharmaceuticals has expanded its biosimilar pipeline to five by bringing in rights in Taiwan and South East Asia markets to Chong Kun Dang Pharmaceutical’s biosimilar of Kyowa Kirin’s Nesp (darbepoetin alfa).
Japan Approves Biosimilar Teriparatide And Darbepoetin
Japan’s first biosimilar teriparatide has been approved for Mochida Pharmaceutical, while competition in the darbepoetin alfa arena looks set to step up following two recent authorizations.